Bend Bioscience Capacity Update April 2025: Small Molecule

The newly unified Bend Bioscience brings together expertise from three specialized CDMOs—Bend, OR, Clearwater, FL, and Gainesville, GA—to provide comprehensive small molecule solutions from pre-clinical development through commercial manufacturing.

The Georgia facility specializes in large-scale oral solid dosage (OSD) manufacturing, with a focus on modified release formulations, multiparticulates, and advanced coating technologies. Spanning over 120,000 square feet, the site supports R&D, clinical, and commercial production, including DEA Schedule I-V controlled substances and high-potency compounds. Key capabilities include late-phase tech transfers, commercial manufacturing, packaging, analytical services, and solvent processing.

With a long-standing history of commercial readiness, the facility maintains a strong track record of reliable, on-time cGMP supply, achieving 100% on-time delivery. Backed by a team of 150 professionals, the Bend Bioscience Georgia facility delivers high-quality pharmaceutical solutions with speed, flexibility, and scientific excellence.